Market Research Logo

Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

Asthma Therapeutics in Asia-Pacific Markets to 2021 - High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns

Rising Prevalence and Increasing Disease Awareness to Drive Significant Growth

The prevalence of asthma in the assessed countries is a prominent contributor towards the market size. In the Asia-Pacific region, the prevalence of asthma is high in the aging population and in children (Song et al., 2014). As the aging population in this region increases, it will lead to greater asthma prevalence. Moreover, the severity of asthma is commonly higher in the aging population, meaning elderly patients will require more medications to control their symptoms, which will also drive the market (Kopnina, 2012). In addition to the aging population, other factors such as increases in air pollution, dust, and pollen levels also contribute to the increase in asthma prevalence (Nadkar et al., 2015). Air pollution leads to both the occurrence of the disease and its exacerbation in children, and there is growing evidence of asthma symptoms in children who live near roadways in high traffic zones (Kopnina, 2012).

Awareness of the disease condition In the Asia-Pacific region is increasing among the public, resulting in an increase in diagnosis and treatment rates. As more number of patients receive drug treatment, this again will drive the market.

There are six costly biologics that are set to enter the Asia-Pacific asthma therapeutics market. These consist of mepolizumab, reslizumab, lebrikizumab, dupilumab, tralokinumab, and benralizumab, which are being developed by GlaxoSmithKline (GSK), Teva, Chugai/Roche, Sanofi/Regeneron, AstraZeneca, and AstraZeneca, respectively.

New Market Entrants Will Boost Market Growth During Forecast Period

These new products will help to diminish the impact of increased generic competition over the forecast period. Currently, there is no approved therapy for the treatment of severe eosinophilic asthma, which creates a significant unmet need in this sub-set patient population. However, among the six biologics in late-stage development, four biologics – mepolizumab, reslizumab, dupilumab, and benralizumab – are being developed for the treatment of severe eosinophilic asthma, and if approved they will address the unmet need.

There are six promising biologics in late-stage development, and four of them are expected to address the current unmet need that exists for the treatment of severe eosinophilic asthma. However, all of these biologics are likely to be priced highly, and hence affordability will be a strong barrier that will restrict the overall market growth. In India, among the six late-stage biologics, only reslizumab is under development, despite the fact that India has the highest asthma prevalence population across the five Asia-Pacific markets. Similarly, in China, only mepolizumab is under development, despite China having the second highest asthma prevalence population after India. In addition, the only approved biologic – Xolair (omalizumab) – is yet to be approved in China, and although it has been available in India since before 2009, its market uptake there is negligible. These findings clearly indicate that there is significant drug affordability concern in India and China.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.6 Classification
2.7 Treatment Guidelines and Options
2.7.1 ICS Monotherapy for the Maintenance Treatment of Asthma
2.7.2 Montelukast sodium as First-Line Maintenance Therapy
2.7.3 ICS/LABA Combination Therapy
2.7.4 Add-on Therapies
3 Marketed Products
3.1 Overview
3.2 ICS for the Maintenance Treatment of Asthma
3.2.1 Arnuity (fluticasone furoate)
3.3 ICS/LABA Combination Therapy for the Maintenance Treatment of Asthma
3.3.1 Seretide/Adoair (fluticasone propionate and salmeterol xinafoate) - GlaxoSmithKline
3.3.2 Symbicort (budesonide and formoterol fumarate) - AstraZeneca, Co-Promotion with Astellas Pharma
3.3.3 Relvar/Breo (vilanterol trifenatate and fluticasone furoate) - GlaxoSmithKline
3.3.4 Flutiform (fluticasone propionate and formoterol fumarate) - SkyePharma
3.4 Add-on Therapy to ICS or ICS/LABA Therapies for the Maintenance Treatment of Asthma
3.4.1 Xolair (omalizumab) - Novartis and Genentech
3.4.2 Montelukast sodium
3.4.3 Spiriva (tiotropium bromide) - Boehringer Ingelheim
3.5 Comparative Efficacy and Safety of Marketed Products
4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Molecules
4.4.1 Mepolizumab - GlaxoSmithKline
4.4.2 Reslizumab - Teva Pharmaceutical
4.4.3 Lebrikizumab - Roche/Genentech
4.4.4 Dupilumab - Regeneron Pharmaceuticals in Collaboration with Sanofi
4.4.5 Tralokinumab - AstraZeneca
4.4.6 Benralizumab - AstraZeneca
4.5 Comparative Efficacy and Safety of Pipeline Products
5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Stage of Development by Molecule Type and Molecular Target
5.2.2 Patient Enrollment per Trial by Stage of Development by Molecule Type and Molecular Target
5.3 Clinical Trial Duration
5.3.1 Trial Duration by Stage of Development by Molecule Type and Molecular Target
5.4 Summary of Clinical Trial Metrics
6 Multi-Scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size
7 Drivers and Barriers
7.1 Drivers
7.1.1 Rising Prevalence
7.1.2 New Costly Market Entries
7.1.3 Growing Alternative Therapeutic Choices
7.2 Barriers
7.2.1 Usage of Traditional Medicines
7.2.2 Treatment Regimen Adherence
7.2.3 Limited Understanding of Underlying Causes
7.2.4 Lack of Awareness and Affordability of High-Cost Biological Products
8 Deals and Strategic Consolidations
8.1 Co-development Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
8.1.4 Key Co-Development Deals
8.2 Licensing Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type and Molecular Target
8.2.4 Key Licensing Deals
9 Appendix
9.1 All Pipeline Drugs by Phase of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Phase I
9.1.4 Phase II
9.1.5 Phase III
9.1.6 Pre-registration
9.2 Summary of Multi-Scenario Market Forecasts to 2021
9.2.1 Asia-Pacific
9.2.2 China
9.2.3 India
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 References
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis
9.6 Contact Us
9.7 Disclaimer
1.1 List of Tables
Table 1: Asthma Therapeutics Market, Global, Classification of Asthma Severity According to GINA Guidelines (2002)
Table 2: Asthma Therapeutics, Global, Management of Chronic Asthma in Adults and Children above Five Years
Table 3: Asthma Diagnosis, Global, Symptoms and Management of Acute Asthma
Table 4: Asthma Trials, Global, Clinical Trial Endpoints
Table 5: Asthma Therapeutics, Global, All Pipeline Products, Discovery, 2015
Table 6: Asthma Therapeutics, Global, All Pipeline Products, Preclinical, 2015
Table 7: Asthma Therapeutics, Global, All Pipeline Products, Phase I, 2015
Table 8: Asthma Therapeutics, Global, All Pipeline Products, Phase II, 2015
Table 9: Asthma Therapeutics, Global, All Pipeline Products, Phase III, 2015
Table 10: Asthma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2015
Table 11: Asthma Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
Table 12: Asthma Therapeutics Market, China, Market Forecast, 2014-2021
Table 13: Asthma Therapeutics Market, India, Market Forecast, 2014-2021
Table 14: Asthma Therapeutics Market, Australia, Market Forecast, 2014-2021
Table 15: Asthma Therapeutics Market, South Korea, Market Forecast, 2014-2021
Table 16: Asthma Therapeutics Market, Japan, Market Forecast, 2014-2021
1.2 List of Figures
Figure 1: Asthma Therapeutics Market, Asia-Pacific, Heat Map for Marketed Products, 2015
Figure 2: Asthma Therapeutics Market, Asia-Pacific, Heat Map for Marketed Products (continued), 2015
Figure 3: Asthma Therapeutics Market, Global, Pipeline, 2015
Figure 4: Asthma Therapeutics Market, Global, Pipeline by Molecular Target, 2015
Figure 5: Asthma Therapeutics Market, Asia-Pacific, Mepolizumab Forecast ($m), 2016-2021
Figure 6: Asthma Therapeutics Market, Asia-Pacific, Reslizumab Forecast ($m), 2016-2021
Figure 7: Asthma Therapeutics Market, Asia-pacific, Lebrikizumab Forecast ($m), 2018-2021
Figure 8: Asthma Therapeutics Market, Asia-Pacific, Dupilumab Forecast ($m), 2019-2021
Figure 9: Asthma Therapeutics Market, Asia-Pacific, Tralokinumab Forecast ($m), 2019-2021
Figure 10: Asthma Therapeutics Market, Asia-Pacific, Benralizumab Forecast ($m), 2020-2021
Figure 11: Asthma Therapeutics Market, Global, Heat Map for Pipeline Products, 2015
Figure 12: Asthma Therapeutics Market, Global, Competitor Matrix for Marketed and Pipeline Products, 2015
Figure 13: Asthma Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2015
Figure 14: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type, 2006-2015
Figure 15: Asthma Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target, 2006-2015
Figure 16: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015
Figure 17: Asthma Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecular Target, 2006-2015
Figure 18: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecule Type, 2006-2015
Figure 19: Asthma Therapeutics, Global, Clinical Trial Size per Individual Trial by Stage of Development and Molecular Target, 2006-2015
Figure 20: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecule Type, 2006-2015
Figure 21: Asthma Therapeutics, Global, Clinical Trial Duration by Phase and Molecular Target, 2006-2015
Figure 22: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 23: Asthma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 24: Asthma Therapeutics Market, Asia-Pacific, Treatment Patterns, 2014-2021
Figure 25: Asthma Therapeutics Market, Asia-Pacific, Market Size ($bn), 2014-2021
Figure 26: Asthma Therapeutics Market, India, Treatment Patterns, 2014-2021
Figure 27: Asthma Therapeutics Market, India, Annual Cost of Therapy ($), 2014-2021
Figure 28: Asthma Therapeutics Market, India, Market Size, 2014-2021
Figure 29: Asthma Therapeutics Market, China, Treatment Patterns, 2014-2021
Figure 30: Asthma Therapeutics Market, China, Annual Cost of Therapy ($), 2014-2021
Figure 31: Asthma Therapeutics Market, China, Market Size, 2014-2021
Figure 32: Asthma Therapeutics Market, Australia, Treatment Patterns, 2014-2021
Figure 33: Asthma Therapeutics Market, Australia, Annual Cost of Therapy ($), 2014-2021
Figure 34: Asthma Therapeutics Market, Australia, Market Size, 2014-2021
Figure 35: Asthma Therapeutics Market, South Korea, Treatment Patterns, 2014-2021
Figure 36: Asthma Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2014-2021
Figure 37: Asthma Therapeutics Market, South Korea, Market Size, 2014-2021
Figure 38: Asthma Therapeutics Market, Japan, Treatment Patterns, 2014-2021
Figure 39: Asthma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2014-2021
Figure 40: Asthma Therapeutics Market, Japan, Market Size ($bn), 2014-2021
Figure 41: Asthma Therapeutics Market, Global, Co-Development Deals by Region, 2006-2015
Figure 42: Asthma Therapeutics Market, Global, Co-Development Deals by Value ($m), 2006-2015
Figure 43: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-Development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015
Figure 44: Asthma Therapeutics Market, Global, Co-Development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
Figure 45: Asthma Therapeutics Market, Global, Co-Development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
Figure 46: Asthma Therapeutics Market, Global, Co-Development Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015
Figure 47: Asthma Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
Figure 48: Asthma Therapeutics Market, Global, Licensing Deals by Value ($m), 2006-2015
Figure 49: Asthma Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015
Figure 50: Asthma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
Figure 51: Asthma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
Figure 52: Asthma Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006-2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report